Phase III
The drug failed to meet statistical significance for overall survival. However, the company is putting a positive spin on it, saying it showed a clear improvement trend in OS for patients treated with Opdivo compared to sorafenib.
Plenty of biopharma companies released results from clinical trials last week. Here’s a look at the top stories.
The Phase III trial paired Exelixis and Genentech’s Cotellic with a checkpoint inhibitor in advanced melanoma.
Bavarian Nordic A/S announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects.
Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial.
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
The drug showed a statistically significant and clinically meaningful improvement in overall abdominal symptoms compared to placebo for all primary and secondary endpoints.
The trial found that Sci-B-Vac was non-inferior to Engerix-B, two of its primary endpoints, but it did not reach the secondary endpoint.
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, reported top-line results from the phase 3 DISCOVER 1 and 2 studies in a press release issued.
Data Supporting the Potential of Voxelotor as a Disease-Modifying Treatment for Sickle Cell Disease (SCD) Published in The New England Journal of Medicineandto bePresented During Presidential Symposium at the 24thEuropean Hematology Association (EHA) Congress
PRESS RELEASES